ArticleCell reports2018
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 491 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
491citing papers in PubMed, 4 pooled it
66.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
491 citing papers in PubMed, 4 syntheses or guidelines pooled it, 787 citations in OpenAlex.
- Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Characteristics, aetiology and implications for management of multiple primary renal tumours: a systematic review.European journal of human genetics : EJHG · 2024Pooled it
- Diagnostic accuracy of deep learning in detection and prognostication of renal cell carcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Guideline
- Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma.European urology oncology · 2025Trial
- Clinical outcomes of metastatic non-clear cell renal cell carcinoma: a real-world single-centre experience.Annals of medicine · 2026Article
- Exploring regulated cell death in renal cell carcinoma: mechanistic insights and therapeutic perspectives.Apoptosis : an international journal on programmed cell death · 2026Review
- Integrated metabolomics data analysis to generate mechanistic hypotheses with MetaProViz.Molecular systems biology · 2026Article
- Molecular underpinnings of metastatic small renal masses.JCI insight · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC).Oncogene · 2026Article
- Dietary Polyphenol Acteoside-Related Molecular Signatures in Clear Cell Renal Cell Carcinoma: Multi-Omics Profiling and Functional Validation of IMPDH1.Food science & nutrition · 2026Article
- PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.Signal transduction and targeted therapy · 2026Review
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.Nature communications · 2026Article
- Article
- [Clinicopathological and molecular features of acquired cystic kidney disease and associated renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes.Cell reports · 2026Article
- SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma.Cancer research · 2026Article
- A benchmark study of vision and pathology foundation models for computational pathology.Nature communications · 2026Article
431 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
46 authors at 20 institutions in 2 countries.
Christopher J RickettsUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
Aguirre A De CubasVanderbilt University School of Medicine, Nashville, TN 37232, USA.
Huihui FanVan Andel Research Institute, Grand Rapids, MI 49503, USA.
Christof C SmithLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Martin LangUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
Ed ReznikMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Reanne BowlbyCanada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
Ewan A GibbCanada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
Rehan AkbaniThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rameen BeroukhimThe Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Donald P BottaroUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
Toni K ChoueiriDana-Farber Cancer Institute, Boston, MA 02215, USA.
Richard A GibbsBaylor College of Medicine, Houston, TX 77030, USA.
Andrew K GodwinUniversity of Kansas Medical Center, Kansas City, KS 66206, USA.
Scott HaakeVanderbilt University School of Medicine, Nashville, TN 37232, USA.
A Ari HakimiMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elizabeth P HenskeBrigham and Women's Hospital, Boston, MA 02115, USA.
James J HsiehWashington University School of Medicine, St. Louis, MO 63110, USA.
Thai H HoMayo Clinic Arizona, Phoenix, AZ 85054, USA.
Rupa S KanchiThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bhavani KrishnanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David J KwiatkowskiBrigham and Women's Hospital, Boston, MA 02115, USA.
Wenbin LiuThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Maria J MerinoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Gordon B MillsThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jerome MyersCentura Health, Centennial, CO 80112, USA.
Michael L NickersonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Victor E ReuterMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Laura S SchmidtUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA; Basic Science Program, Leidos Biomedical Research, Inc. Frederick National Laboratory of Cancer Research, Frederick, MD 21702, USA.
C Simon ShelleyLeukemia Therapeutics LLC., Hull, MA 02045, USA.
Hui ShenVan Andel Research Institute, Grand Rapids, MI 49503, USA.
Brian ShuchYale University, New Haven, CT 06520, USA.
Sabina SignorettiDana-Farber Cancer Institute, Boston, MA 02215, USA.
Ramaprasad SrinivasanUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
Pheroze TamboliThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
George ThomasOregon Health & Science University, Portland, OR 97239, USA.
Benjamin G VincentLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Cathy D VockeUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA.
David A WheelerBaylor College of Medicine, Houston, TX 77030, USA.
Lixing YangHarvard Medical School, Boston, MA 02115, USA.
William Y KimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
A Gordon RobertsonCanada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
Cancer Genome Atlas Research Network
Paul T SpellmanOregon Health & Science University, Portland, OR 97239, USA.
W Kimryn RathmellVanderbilt University School of Medicine, Nashville, TN 37232, USA.
W Marston LinehanUrologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA. Electronic address: wml@nih.gov.
National Cancer Institute · USCanada's Michael Smith Genome Sciences Centre · CABaylor College of Medicine · USOregon Health & Science University · USThe University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · USVanderbilt University · USHarvard University · USLeidos (United States) · USMemorial Sloan Kettering Cancer Center · USUniversity of Kansas Medical Center · USVan Andel Institute · USDana-Farber Cancer Institute · USLeukemia Research Foundation · USBrigham and Women's Hospital · USWashington University in St. Louis · USYale University · USSt. Anthony Hospital · USBroad Institute · USMayo Clinic Hospital · US
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MLarge Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7MX-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MThe Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MVirology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MGene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8MGenome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MThe Cancer Genome Atlas Data Analysis CenterU24CA143845 · NCI · BROAD INSTITUTE, INC. · PI CHIN, LYNDA, GETZ, GAD A · 2009 to 2016
$16.0MHarvard Genome Characterization CenterU24CA144025 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHERLAPATI, RAJU S. · 2009 to 2016
$14.0MThe USC-JHU Cancer Epigenome Characterization CenterU24CA143882 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BAYLIN, STEPHEN B., WEISENBERGER, DANIEL JOSEPH · 2009 to 2016
$13.3MNCI NIH HHS HHSN261200800001ENCI NIH HHS K12 CA090625NCI NIH HHS K24 CA172355NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA163722NCI NIH HHS R01 CA169172NCI NIH HHS U24 CA143799NCI NIH HHS U24 CA143835NCI NIH HHS U24 CA143840NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143866NCI NIH HHS U24 CA143867NCI NIH HHS U24 CA143882NCI NIH HHS U24 CA143883NCI NIH HHS U24 CA144025NCI NIH HHS U24 CA210949NCI NIH HHS U24 CA210950NCI NIH HHS U24 CA210957NCI NIH HHS U24 CA210969NCI NIH HHS U24 CA210990NHGRI NIH HHS U54 HG003067NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG003273
Abstract
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival.
Indexed as
Genome, HumanBiomarkers, TumorCarcinoma, Renal CellCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsHumansKidney NeoplasmsMetabolic Networks and PathwaysNuclear ProteinsPhenotypePTEN PhosphohydrolaseSurvival AnalysisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA-Binding ProteinsNuclear ProteinsPBRM1 protein, humanPTEN PhosphohydrolasePTEN protein, humanTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseCDKN2Achromatin remodelingchromophobe renal cell carcinomaclear cell renal cell carcinomaDNA hypermethylationimmune signaturePanCanAtlaspapillary renal cell carcinomaTCGA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.